Significant mitral regurgitation after permanent right ventricular pacemaker implantation: prognostic implications.

echocardiography heart failure mitral regurgitation pacemaker valvular disease

Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
07 May 2024
Historique:
received: 03 02 2024
revised: 25 04 2024
accepted: 05 05 2024
medline: 10 5 2024
pubmed: 10 5 2024
entrez: 9 5 2024
Statut: aheadofprint

Résumé

The underlying mechanisms leading to the development of mitral regurgitation (MR) after right ventricular (RV) pacemaker (PM) implantation and its prognostic value have yet to be fully understood. The purpose of this study was to evaluate the prevalence and clinical variables associated with the development of MR after RV pacing and its association with outcomes. A total of 451 patients (mean age 69 ± 15 years, 61% male) who underwent de novo RV PM implantation were included. The development of significant MR, defined as ≥ moderate from mild or none/trace at baseline, occurred in 131 (29%) patients at a median of 2.4 years [interquartile range (IQR): 1.0-3.8 years] after PM implantation. Multivariate logistic regression analysis demonstrated that implantation of a single-chamber PM, LV end-systolic volume index and the presence of mild MR (vs no MR) at baseline were independently associated with the development of significant MR post-implant. Cardiac events, defined as the composite of all-cause mortality or heart failure hospitalization, occurred in 143 patients (31.7%) during a median follow-up of 5.4 years [IQR: 3.0-8.1 years]. Multivariate Cox regression analysis demonstrated that the development of significant MR was independently related to the occurrence of cardiac events. In conclusion, the development of significant MR after PM implantation is seen in about one third of recipients and is independently associated with adverse cardiac events.

Identifiants

pubmed: 38723856
pii: S0002-9149(24)00356-4
doi: 10.1016/j.amjcard.2024.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Takeru Nabeta (T)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: takerunabeta@gmail.com.

Xavier Galloo (X)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Laurens Tops (L)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Jan Stassen (J)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Department of Cardiology, Jessa Hospital, Hasselt, Belgium.

Nina Ajmone Marsan (NA)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Pieter van der Bijl (P)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Jeroen J Bax (JJ)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; Heart Centre, University of Turku and Turku University Hospital, Turku, Finland.

Classifications MeSH